Interim report May 1 - July 31 2009
Oasmia Pharmaceutical AB (publ)
Interim Report for the period May 1 - July 31 2009
CONTINUED FOCUS ON CLINICAL TRIALS
THE PERIOD IN BRIEF May - July 2009
• Net sales for the Group amounted to TSEK 24 657 (44 605)
• Operating income amounted to TSEK 10 624 (24 124)
• Net income after tax amounted to TSEK 9 386 (24 129)
• Earnings per share amounted to SEK 0,28 (0,72 kr)
• Comprehensive income amounted to TSEK 9 386 (24 129)
• Oasmia announced a multi-year agreement for distribution of Paccal® Vet, a unique pharmaceutical for treatment of cancer in the USA and Canada.
• An Extraordinary General Meeting made a resolution to adopt the Board of Directors' proposal of new share issue with deviation from shareholders' preferential rights, and the Board's proposal of new share issue with shareholders' preferential rights.
EVENTS AFTER CLOSING DAY
• The new share issue with shareholders' preferential rights was fully subscribed.
• The new share issue with deviation from shareholders' preferential rights was ended without any subscriptions.
The report is available in PDF-format here.
